vs
ICU MEDICAL INC（ICUI）与PROCORE TECHNOLOGIES, INC.（PCOR）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是PROCORE TECHNOLOGIES, INC.的1.5倍（$540.7M vs $349.1M），ICU MEDICAL INC净利率更高（-2.9% vs -10.8%，领先7.9%），PROCORE TECHNOLOGIES, INC.同比增速更快（15.6% vs -14.1%），PROCORE TECHNOLOGIES, INC.自由现金流更多（$109.2M vs $36.0M），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（13.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
ICUI vs PCOR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $349.1M |
| 净利润 | $-15.7M | $-37.6M |
| 毛利率 | 37.5% | 80.1% |
| 营业利润率 | 1.0% | -12.3% |
| 净利率 | -2.9% | -10.8% |
| 营收同比 | -14.1% | 15.6% |
| 净利润同比 | 34.0% | 39.6% |
| 每股收益（稀释后） | $-0.63 | $-0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $540.7M | $349.1M | ||
| Q3 25 | $537.0M | $338.9M | ||
| Q2 25 | $548.9M | $323.9M | ||
| Q1 25 | $604.7M | $310.6M | ||
| Q4 24 | $629.8M | $302.0M | ||
| Q3 24 | $589.1M | $295.9M | ||
| Q2 24 | $596.5M | $284.3M | ||
| Q1 24 | $566.7M | $269.4M |
| Q4 25 | $-15.7M | $-37.6M | ||
| Q3 25 | $-3.4M | $-9.1M | ||
| Q2 25 | $35.3M | $-21.1M | ||
| Q1 25 | $-15.5M | $-33.0M | ||
| Q4 24 | $-23.8M | $-62.3M | ||
| Q3 24 | $-33.0M | $-26.4M | ||
| Q2 24 | $-21.4M | $-6.3M | ||
| Q1 24 | $-39.5M | $-11.0M |
| Q4 25 | 37.5% | 80.1% | ||
| Q3 25 | 37.4% | 79.7% | ||
| Q2 25 | 37.9% | 79.1% | ||
| Q1 25 | 34.7% | 79.1% | ||
| Q4 24 | 36.1% | 81.2% | ||
| Q3 24 | 34.8% | 81.4% | ||
| Q2 24 | 34.8% | 83.1% | ||
| Q1 24 | 32.7% | 83.0% |
| Q4 25 | 1.0% | -12.3% | ||
| Q3 25 | 2.6% | -4.4% | ||
| Q2 25 | 1.9% | -9.3% | ||
| Q1 25 | 2.1% | -11.7% | ||
| Q4 24 | 6.0% | -21.9% | ||
| Q3 24 | 1.4% | -12.3% | ||
| Q2 24 | 1.3% | -5.2% | ||
| Q1 24 | -1.9% | -7.0% |
| Q4 25 | -2.9% | -10.8% | ||
| Q3 25 | -0.6% | -2.7% | ||
| Q2 25 | 6.4% | -6.5% | ||
| Q1 25 | -2.6% | -10.6% | ||
| Q4 24 | -3.8% | -20.6% | ||
| Q3 24 | -5.6% | -8.9% | ||
| Q2 24 | -3.6% | -2.2% | ||
| Q1 24 | -7.0% | -4.1% |
| Q4 25 | $-0.63 | $-0.25 | ||
| Q3 25 | $-0.14 | $-0.06 | ||
| Q2 25 | $1.43 | $-0.14 | ||
| Q1 25 | $-0.63 | $-0.22 | ||
| Q4 24 | $-0.97 | $-0.42 | ||
| Q3 24 | $-1.35 | $-0.18 | ||
| Q2 24 | $-0.88 | $-0.04 | ||
| Q1 24 | $-1.63 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $768.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $1.3B |
| 总资产 | $4.1B | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $768.5M | ||
| Q3 25 | — | $684.0M | ||
| Q2 25 | — | $620.9M | ||
| Q1 25 | — | $566.7M | ||
| Q4 24 | $308.6M | $775.4M | ||
| Q3 24 | $312.5M | $756.9M | ||
| Q2 24 | $302.6M | $735.4M | ||
| Q1 24 | $251.4M | $744.6M |
| Q4 25 | $2.1B | $1.3B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.0B | $1.2B | ||
| Q4 24 | $2.0B | $1.3B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $2.0B | $1.3B | ||
| Q1 24 | $2.1B | $1.2B |
| Q4 25 | $4.1B | $2.2B | ||
| Q3 25 | $4.1B | $2.1B | ||
| Q2 25 | $4.1B | $2.0B | ||
| Q1 25 | $4.2B | $1.9B | ||
| Q4 24 | $4.2B | $2.1B | ||
| Q3 24 | $4.3B | $2.0B | ||
| Q2 24 | $4.3B | $2.0B | ||
| Q1 24 | $4.3B | $1.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $114.9M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $109.2M |
| 自由现金流率自由现金流/营收 | 6.6% | 31.3% |
| 资本支出强度资本支出/营收 | 4.6% | 1.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | $282.2M |
8季度趋势，按日历期对齐
| Q4 25 | $60.6M | $114.9M | ||
| Q3 25 | $56.7M | $88.5M | ||
| Q2 25 | $11.2M | $30.8M | ||
| Q1 25 | $51.3M | $66.0M | ||
| Q4 24 | $40.2M | $29.1M | ||
| Q3 24 | $36.1M | $39.3M | ||
| Q2 24 | $82.0M | $58.7M | ||
| Q1 24 | $45.8M | $69.1M |
| Q4 25 | $36.0M | $109.2M | ||
| Q3 25 | $27.6M | $83.1M | ||
| Q2 25 | $-8.5M | $27.9M | ||
| Q1 25 | $36.7M | $62.0M | ||
| Q4 24 | $16.1M | $17.4M | ||
| Q3 24 | $16.2M | $35.7M | ||
| Q2 24 | $62.5M | $56.8M | ||
| Q1 24 | $29.9M | $67.1M |
| Q4 25 | 6.6% | 31.3% | ||
| Q3 25 | 5.1% | 24.5% | ||
| Q2 25 | -1.5% | 8.6% | ||
| Q1 25 | 6.1% | 20.0% | ||
| Q4 24 | 2.6% | 5.8% | ||
| Q3 24 | 2.7% | 12.1% | ||
| Q2 24 | 10.5% | 20.0% | ||
| Q1 24 | 5.3% | 24.9% |
| Q4 25 | 4.6% | 1.6% | ||
| Q3 25 | 5.4% | 1.6% | ||
| Q2 25 | 3.6% | 0.9% | ||
| Q1 25 | 2.4% | 1.3% | ||
| Q4 24 | 3.8% | 3.9% | ||
| Q3 24 | 3.4% | 1.2% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 2.8% | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
